Early research (Phase 1)Study completedNCT02262910What this trial is testingStudy of ES414 in Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer Aptevo Therapeutics 35
Early research (Phase 1)WithdrawnNCT03110588What this trial is testingPhase I Trial of PACE for Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer University of Alabama at Birmingham
Early research (Phase 1)Study completedNCT00327288What this trial is testingSafety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer PatientsWho this might be right forNon-small Cell Lung CancerBreast CancerProstate Cancer AmpliMed Corporation 34
Not applicableApproved For MarketingNCT01606982What this trial is testingProvide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyWho this might be right forMetastatic Castration-Resistant Prostate Cancer Astellas Pharma Global Development, Inc.
Early research (Phase 1)Active Not RecruitingNCT03523442What this trial is testingAndrogen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate CancerWho this might be right forProstatic Neoplasms Janssen Research & Development, LLC 19
Early research (Phase 1)Study completedNCT04628988What this trial is testingCC-90011 and Comparators in Participants With Prostate CancerWho this might be right forProstatic Neoplasms Celgene 6
Not applicableWithdrawnNCT03596710What this trial is testingImage-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand TherapyWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer Jonsson Comprehensive Cancer Center
Not applicableStudy completedNCT03329742What this trial is testingSipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate CancerWho this might be right forProstate Cancer Recurrent Indiana University 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT04253262What this trial is testingCopanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer Brown University 13
Testing effectiveness (Phase 2)Looking for participantsNCT07181161What this trial is testingStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer AstraZeneca 283
Testing effectiveness (Phase 2)Looking for participantsNCT06970119What this trial is testingA Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate CancerWho this might be right forProstate Cancer Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Early research (Phase 1)Looking for participantsNCT05613894What this trial is testingDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer University of Utah 33
Not applicableLooking for participantsNCT06600802What this trial is testingIntrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerWho this might be right forCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA) Centre Jean Perrin 120
Testing effectiveness (Phase 2)Study completedNCT01748500What this trial is testingPantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer University Health Network, Toronto 21
Testing effectiveness (Phase 2)Study completedNCT01240629What this trial is testingDoxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWho this might be right forProstate CancerHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more University of Southern California 43
Testing effectiveness (Phase 2)Ended earlyNCT04951492What this trial is testingOlaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaWho this might be right forCastration-Resistant Prostate CarcinomaProstate Adenocarcinoma University of Washington 2
Testing effectiveness (Phase 2)Looking for participantsNCT06457919What this trial is testingTinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerWho this might be right forProstate Cancer Memorial Sloan Kettering Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT00140400What this trial is testingPrime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate CancerWho this might be right forProstate Cancer Cell Genesys 50
Large-scale testing (Phase 3)Study completedNCT00134056What this trial is testingS0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyWho this might be right forMetastatic CancerProstate Cancer SWOG Cancer Research Network 1,038
Early research (Phase 1)Looking for participantsNCT06943495What this trial is testingPersonalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)Who this might be right forMetastatic Castrate Resistant Prostate Cancer (mCRPC) Jean-Mathieu Beauregard 60